{"entity":{"id":"nct05201404","kind":"trial","name":"Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis","aka":[],"tldr":"A phase 3 trial of Namodenoson in hepatocellular carcinoma, run by Can-Fite BioPharma, now recruiting.","summary":"Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis is a phase 3 interventional study registered as NCT05201404 by Can-Fite BioPharma, with 471 participants planned, started 2023-03-15 and due to reach its primary completion in 2026-02. Interventions recorded: Namodenoson and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05201404","url":"https://clinicaltrials.gov/study/NCT05201404"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["can-fite"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05201404","phase":"3","setting":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis","sponsor":"Can-Fite BioPharma","enrolled":471,"outcomes":[]},"route":"/trials/nct05201404/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"company":[{"id":"can-fite","kind":"company","name":"Can-Fite BioPharma","route":"/companies/can-fite/"}]}}